29th Annual ROTH Conference
March 12-15, 2017
Ritz Carlton, Dana Point, CA
ROTH Capital Partners' 29th Annual Conference is one of the largest of its kind in the United States. With roughly 500 participating companies and over 4,000 attendees, Roth will feature presentations from hundreds of public and private companies in a variety of sectors including health care; technology, Internet and media; cleantech, industrial growth and solar; consumer; oil and gas/mining and minerals; and business services. The three-and-a-half day event will include company presentations and small group meetings, as well as panels, entertainment and more. This gathering of institutional investors, private equity investors, VCs, company executives and service providers has become a must attend event for anyone working in the small and mid-cap space. For more information visit www.Roth.com
U.S. Auto Parts Network (PRTS)
U.S. Auto Parts Network (NASDAQ: PRTS) operates as an online retailer of aftermarket auto parts and accessories primarily in the United States, Canada, and the Philippines. It offers body parts, such as parts for the exterior of an automobile; mirror products; engine parts comprising engine and chassis components, as well as other mechanical and electrical parts; and performance parts and accessories to individual consumers through its network of websites and online marketplaces. The company also sells and delivers auto parts to collision repair shops; and markets Kool-Vue products to auto parts wholesale distributors. For more information, visit the company's website at www.usautoparts.net.
U.S. Geothermal (HTM)
U.S. Geothermal (NYSE: HTM) is a renewable energy company that focuses on the development, production, and sale of electricity from geothermal energy in the Western United States. The company operates geothermal power projects with a total power generation capacity of approximately 45 MWs located at Neal Hot Springs, Oregon; San Emidio, Nevada; and Raft River, Idaho. It is also developing an additional 90 MWs of projects at the Geysers, California; a second phase project at San Emidio, Nevada; and Crescent Valley, Nevada, as well as the El Ceibillo project located near Guatemala City, Guatemala. U.S. For more information, visit the company's website at www.usgeothermal.com.
UniPixel (NASDAQ: UNXL) designs, develops, manufactures and markets micro-structured polymer film materials and related technologies for the display, flexible electronics, and automotive industries in the United States. It makes innovative performance-engineered films that enhance and protect touchscreen and flexible electronics products. The company markets its touch screen films under the brand XTouch, as sub-components of a touch sensor module; and hard coat resin and optical films under the Diamond Guard brand. Uni-Pixel Inc. was founded in 1998 and is headquartered in Santa Clara, California. For more information, visit the company's website at www.unipixel.com.
Unique Fabricating (UFAB)
Unique Fabricating (NYSE: UFAB) engineers and manufactures multi-material foam, rubber, and plastic components utilized in noise, vibration, and harshness (NVH), acoustical management, water and air sealing, decorative, and other functional applications. It supplies die cut non-metallic materials and components, which are used in applications, such as air and water sealing, insulation, NVH performance, and BSR conditions; thermoformed and compression molded products, including HVAC air ducts, door watershields, evaporator liners, console bin mats, fender insulators, and others; and fusion molded products comprising exterior mirror seals, cowl-to-hood seals, cowl-to-fender seals, and other products for NVH management and body sealing applications. For more information, visit the company's website at www.uniquefab.com.
Uniroyal Global Engineered Products (UNIR)
Uniroyal Global Engineered Products (OTCQB: UNIR) develops, manufactures and distributes vinyl coated fabrics products that have applications in the automotive and non-automotive transportation, indoor/outdoor furniture, commercial and hospitality seating, healthcare facilities, athletic equipment, and residential primarily in North America and Europe. The company's products in the automotive industry are used primarily in seating, door panels, head and arm rests, security shades, and trim components. Its non-automotive applications include outdoor seating for utility and sports vehicles; and sheeting used in medical, nuclear protection, personal protection, moisture barriers, pram and nursery, movie screen, and decorative surface applications. For more information, visit the company's website at www.uniroyalglobal.com.
Upland Software (UPLD)
Upland Software (NASDAQ: UPLD) provides cloud-based enterprise work management software in the United States and internationally. It offers a family of cloud-based enterprise work management software applications under the Upland brand for the information technology, process excellence, finance, professional services, and marketing functions in organizations. The company's software applications address enterprise work challenges in various categories, including program and portfolio management, project management and collaboration, workflow automation and enterprise content management, digital engagement management, professional services automation, and financial management. It sells its products through a direct sales organization, as well as through distributors and value-added resellers. For more information, visit the company's website at www.uplandsoftware.com.
Uranium Resources (URRE)
Uranium Resources (NASDAQ: URRE) explores for, develops, and produces uranium. The company has in-situ recovery (ISR) projects and two licensed processing facilities. It owns and operates the Temrezli ISR project in Central Turkey; and controls exploration properties under nine exploration and operating licenses covering approximately 32,000 acres with various exploration targets, including the Sefaatli project. The company also holds interest in approximately 190,000 acres of mineral holdings in the prolific Grants Mineral Belt of the State of New Mexico; and 14,000 acres in the South Texas uranium province. In addition, it holds an agreement to acquire certain placer mining claims in the Sal Rica lithium brine project that covers an area of approximately 9,800 acres located in the Pilot Valley region of northwestern Utah. For more information, visit the company's website at www.uraniumresources.com.
UR-Energy (NYSE: URG) engages in the acquisition, exploration, development and operation of uranium mineral properties. The company holds interests in 14 projects located in the United States. Its principal property is the Lost Creek project comprising a total of approximately 2,100 unpatented mining claims and four Wyoming mineral leases covering an area of approximately 42,000 acres located in the Great Divide Basin, Wyoming, For more information, visit the company's website at www.ur-energy.com.
US Energy (USEG)
US Energy (NASDAQ: USEG) is an independent energy company focused on the acquisition and development of oil and gas producing properties in the continental United States. It has oil and gas projects in Williston Basin of North Dakota; Zavala County and Dimmit County in Texas; and in Coastal Louisiana. As of December 31, 2015, the company had estimated proved reserves of 2,028,168 barrels of oil equivalent. It has 118,188 gross acres of leases and 150 gross producing wells. For more information, visit the company's website at www.usnrg.com.
USA Technologies (USAT)
USA Technologies (NASDAQ: USAT) provides wireless networking, cashless transactions, asset monitoring, and other value-added services principally to the small ticket and unattended point of sale (POS) markets in the United States and internationally. The company designs and markets systems and solutions that facilitate electronic payment options, as well as telemetry and machine-to-machine (M2M) services to remotely monitor, control and report on the results of distributed assets containing its electronic payment solutions. Its ePort Connect solution offers POS options, card processing services, wireless connectivity, online sales reporting, M2M telemetry and DEX data transfer, over-the-air update capabilities, deployment planning, and value-added services, as well as premium services comprising planning, project management, installation support, marketing, and performance evaluation. For more information, visit the company's website at www.usatech.com.
Vaalco Energy (EGY)
Vaalco Energy (NYSE: EGY) is an independent energy company that acquires, explores for, develops, and produces crude oil and natural gas in the United States. The company owns producing properties and conducts exploration activities as an operator in Gabon and Angola, as well as conducts exploration activities as a non-operator in Equatorial Guinea, West Africa. It also acts as the operator of unconventional resource properties in North Texas and a lease hold in Montana; and owns minor interests in conventional production activities as a non-operator. For more information, visit the company's website at www.vaalco.com.
Valeritas (OTCQB: VLRX) is a commercial-stage medical technology company focused on improving health and simplifying life for people with diabetes by developing and commercializing innovative technologies. Valeritas' flagship product, V-Go® Wearable Insulin Delivery device, is a simple, wearable, basal-bolus insulin delivery device for patients with Type 2 diabetes that enables patients to administer a continuous preset basal rate of insulin over 24 hours. It also provides discreet on-demand bolus dosing at mealtimes. It is the only basal-bolus insulin delivery device on the market today specifically designed keeping in mind the needs of Type 2 diabetes patients. For more information, visit the company's website at www.valeritas.com.
Vascular Biogenics (VBLT)
Vascular Biogenics (NASDAQ: VBLT), operating as VBL Therapeutics, is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class treatments for cancer. The company's lead oncology product candidate, ofranergene obadenovec (VB-111), is a first-in-class, targeted anti-cancer gene-therapy agent that is positioned to treat a wide range of solid tumors. It is conveniently administered as an IV infusion once every two months. It has been observed to be well-tolerated in >200 cancer patients and we have observed its efficacy signals in an "all comers" phase 1 trial as well as in three tumor-specific phase 2 studies. Ofranergene obadenovec is currently being studied in a phase 3 pivotal trial for recurrent Glioblastoma, conducted under an FDA Special Protocol Assessment (SPA). For more information, visit the company's website at www.vblrx.com.
Veloxis Pharmaceuticals (VELO)
Veloxis Pharmaceuticals (OTC: VELO) operates as a specialty pharmaceutical company in Denmark and the United States. The company's proprietary technology, MeltDose is designed to enhance the absorption and bioavailability of select orally administered drugs. For more information, visit the company's website at www.veloxis.com.
Verastem (NASDAQ: VSTM) is a biopharmaceutical company that focuses on discovering and developing drugs targeting cancer stem cells (CSCs). Its programs target the focal adhesion kinase (FAK) and the PI3K/mTOR signaling pathways. The company's product candidate FAK inhibitor, VS-6063, is in phase I study in combination with PD-1 inhibitor pembrolizumab and gemcitabine for pancreatic cancer; a phase Ib clinical trial in combination with paclitaxel for patients with ovarian cancer; a phase II study in patients with non-small cell lung cancer; a phase II trial preceding surgery in mesothelioma; and a phase I/Ib clinical trial in combination with avelumab in patients with ovarian cancer, as well as a combination trial of VS-6063 and VS-5584 in patients with relapsed mesothelioma. For more information, visit the company's website at www.verastem.com.
Vericel (NASDAQ: VCEL) is a commercial-stage biopharmaceutical company that develops and sells patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions. The company markets two autologous cell therapy products, including Carticel, an autologous chondrocyte implant for the treatment of cartilage defects in the knee; and Epicel, a permanent skin replacement for the treatment of patients with deep-dermal or full-thickness burns comprising greater than or equal to 30 percent of total body surface area in the United States. Vericel is also developing MACI, a third-generation autologous chondrocyte implant for the treatment of cartilage defects in the knee; and ixmyelocel-T, which is in phase IIb clinical trial, a patient-specific multicellular therapy for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy. For more information, visit the company's website at www.aastrom.com.
Vertex Energy (VTNR)
Vertex Energy (NASDAQ: VTNR), an environmental services company, provides a range of services designed to aggregate, process and recycle industrial waste systems and off-specification commercial chemical products. It operates in three divisions: Black Oil, Refining and Marketing, and Recovery. The Black Oil division collects and purchases used motor oil directly from third-party generators; aggregates used motor oil from a network of local and regional collectors; and sells used motor oil to customers for use as a feedstock or replacement fuel for industrial burners. The Refining and Marketing division gathers hydrocarbon streams in the form of petroleum distillates, transmix, and other chemical products that are purchased from pipeline operators, refineries, chemical processing facilities, and third-party providers; and sells end products, such as gasoline blendstock, pygas, and fuel oil cutter stock to oil companies or to petroleum trading and blending companies. For more information, visit the company's website at www.vertexenergy.com.
Veru Healthcare (FHCO)
Veru Healthcare (NASDAQ: FHCO) is a medical therapeutics company, develops, manufactures, and markets consumer health care products. The company's pharmaceuticals product portfolio includes the Tamsulosin delayed release sachet that is under bioequivalence study for the treatment of benign prostatic hyperplasia; MSS-722, a fixed ratio of trans- and cis-clomiphene citrate isomers, which is under the phase II clinical trial to treat male infertility caused by testicular dysfunction; APP-944, a zuclomiphene citrate that is under the phase II clinical trial for the treatment of hot flashes in men on prostate cancer hormonal therapies; and APP-111, an oral tubulin targeting chemotherapy, which is under the preclinical study to treat metastatic prostate, breast, and ovarian cancers, as well as APP-111/112 oral agents that target colchicine binding site of tubulin for the treatment of gout and familial Mediterranean fever. For more information, visit the company's website at www.veruhealthcare.com.
Viking Therapeutics (VKTX)
Viking Therapeutics (NASDAQ: VKTX) is a clinical-stage biopharmaceutical company that focuses on the development of therapies for metabolic and endocrine disorders. Its lead clinical program includes VK0612, an orally available drug candidate for the treatment of Type 2 diabetes. The company is also developing VK5211, an orally available drug candidate, which is in a phase II clinical trial for acute rehabilitation following non-elective hip fracture surgery. In addition, it is developing VK0214, a novel liver-selective thyroid hormone receptor beta agonist for lipid disorders, such as dyslipidemia and nonalcoholic steatohepatitis, as well as VK2809, an orally available, tissue, and receptor-subtype selective agonist of the thyroid beta receptor that is entering phase II development for the treatment of patients with hypercholesterolemia and fatty liver disease. For more information, visit the company's website at www.vikingtherapeutics.com.
Viper Energy Partners (VNOM)
Viper Energy Partners (NASDAQ: VNOM) is a limited partnership formed by Diamondback Energy, Inc. to own, acquire and exploit oil and natural gas properties in North America, with a focus on oil-weighted basins, primarily the Permian Basin in West Texas. Diamondback is an independent oil and natural gas company headquartered in Midland, Texas focused on the acquisition, development, exploration and exploitation of unconventional, onshore oil and natural gas reserves in the Permian Basin in West Texas. Diamondback's activities are primarily focused on the horizontal exploitation of multiple intervals within the Wolfcamp, Spraberry, Clearfork, Bone Spring and Cline formations. For more information, visit the company's website at www.viperenergy.com.
Vista Outdoor (VSTO)
Vista Outdoor (NYSE: VSTO) designs, manufactures and markets consumer products for the outdoor sports and recreation markets worldwide. The company's Shooting Sports segment designs, develops, produces and sources ammunition for the hunting and sport shooting enthusiast markets, as well as for local law enforcement, the United States government, and international markets under the Federal Premium, Speer, American Eagle, Blazer, CCI, Estate Cartridge, Stevens, Fusion, Savage Arms, Savage Range Systems, Force on Force, and Independence brands; and provides firearms products, such as centerfire rifles, rimfire rifles, shotguns, and range systems. Its Outdoor Products segment offers archery/hunting accessories, such as hunting arrows, game calls, hunting blinds, game cameras, and waterfowl decoys; eyewear and sport protection products comprising safety and protective eyewear. For more information, visit the company's website at www.vistaoutdoor.com.
VivoPower International (VVPR)
VivoPower International (NASDAQ: VVPR) builds, finances and operates solar power assets. It offers renewable energy for commercial, industrial and government customers. VivoPower was incorporated in 2016 and is based in London, United Kingdom with additional offices in London, United Kingdom; New York, New York; San Francisco, California; Brisbane and North Sydney, Australia; Singapore; Dallas, Texas; and Manila, Philippines. VivoPower International PLC operates as a subsidiary of Arowana International Limited. For more information, visit the company's website at www.vivopower.com.
VolitionRX (NYSE: VNRX) is a clinical-stage life sciences company that focuses on developing blood-based diagnostic tests for detecting and diagnosing cancer and other diseases. The company is involved in the development of 28 epigenetic NuQ blood assays based on its Nucleosomics biomarker discovery platform. It develops two blood assays in the NuQ-X family to detect the presence of cancer by detecting nucleosomes containing specific nucleotides; and three blood tests in the NuQ-V family to detect cancer by detecting nucleosomes containing specific histone variants. VolitionRX also develops 17 blood assays in the NuQ-M family to detect cancer by detecting nucleosomes containing modified histones that are proteins for packaging and ordering DNA into nucleosomes; 5 blood assays in the NuQ-A family to detect cancer by detecting nucleosome-protein adducts; and a NuQ-T assay to detect cancer by detecting total blood nucleosome levels. For more information, visit the company's website at www.volitionrx.com.
Volt Information Sciences (VISI)
Volt Information Sciences (NYSE: VISI) provides staffing and information technology (IT) infrastructure services in the United States and internationally. It operates through North American Staffing, International Staffing, and Technology Outsourcing Services and Solutions segments. The company provides contingent staffing, direct placement, recruitment process outsourcing, staffing management, and other employment services; and managed service programs consisting of managing the procurement and on-boarding of contingent workers. Volt Information Sciences also offers technology outsourcing services and solutions, such as customer care call centers, and video and online gaming industry quality assurance testing services. For more information, visit the company's website at www.volt.com.
vTv Therapeutics (VTVT)
vTv Therapeutics (NASDAQ: VTVT) is a clinical-stage biopharmaceutical company that discovers, develops and sells orally administered small molecule drug candidates worldwide. The company's drug candidate for the treatment of Alzheimer's disease comprise azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation end-products, which is in Phase III clinical trials. Its Type 2 diabetes drug candidates include TTP399, an orally administered, liver-selective glucokinase activator that has been completed phase IIb clinical trials; and TTP273, an orally administered, non-peptide agonist that targets the glucagon-like peptide-1 receptor, which is in phase II clinical trials. For more information, visit the company's website at www.vtvtherapeutics.com.
W&T Offshore (WTI)
W&T Offshore (NYSE: WTI) is an independent oil and natural gas producer that engages in the acquisition, exploration, and development of oil and natural gas properties in the Gulf of Mexico. The company sells crude oil, natural gas liquids and natural gas. It holds working interests in approximately 54 offshore fields in federal and state waters. As of March 8, 2016, the company had interests in offshore leases covering approximately 900,000 gross acres, including approximately 550,000 gross acres in the Gulf of Mexico Shelf; and approximately 350,000 gross acres in the deep-water. For more information, visit the company's website at www.wtoffshore.com.
Web.com Group (WEB)
Web.com Group (NASDAQ: WEB) provides a range of Internet services to small businesses in North America, South America and the United Kingdom. The company's services and products enable small businesses to establish, maintain, promote and optimize their online presence. It provides domain name registration, such as .com and .net domains, as well as a suite of domain name services. The company also offers Do-It-For-Me Web solutions, including custom websites with built in marketing, analytics, and hosting facilities; Ignite that enables Websites to be promoted in various directories; Facebook Boost by Web.com, which designs or updates the business profile page on Facebook and includes monthly advertising and postings; and eCommerce that designs, setups, and configures the online store and shopping cart. For more information, visit the company's website at www.web.com.
Wilhelmina International (WHLM)
Wilhelmina International (NASDAQ: WHLM) engages in the representation and management of models, entertainers, artists, athletes and other talent to various customers and clients. It offers fashion modeling and talent product-endorsement services to clients, such as advertising agencies, branded consumer goods companies, fashion designers, magazines, retailers, department stores, product catalogs, and Internet sites. The company also provides photography, styling and hair and makeup services to various companies in the retail, pharmaceutical, and music industries; and talent management services. For more information, visit the company's website at www.wilhelmina.com.
Willdan Group (WLDN)
Willdan Group (NASDAQ: WLDN) provides professional technical and consulting services to utilities, private industry, and public agencies at various levels of government primarily in the Unites States. The Energy Efficiency Services segment offers comprehensive surveys, program design, master planning, benchmarking analysis. The Engineering Services segment provides a range of engineering related services, such as building and safety, city engineering, code enforcement, development plan review and inspection, disaster recovery, environmental consulting and remediation. Willdan's Public Finance Services segment offers district administration, financial consulting, and federal compliance services. The Homeland Security Services segment provides emergency preparedness planning, training, and exercises. The company serves public and governmental agencies, including cities, counties, redevelopment agencies, water districts, school districts, and universities. For more information, visit the company's website at www.willdan.com.
Workiva (NYSE: WK) provides a cloud-based and mobile-enabled platform for enterprises to collect, manage, report, and analyze critical business data in real time. It offers solutions for compliance, risk, finance, accounting, and audit management. The company's Wdesk productivity platform allows multiple users to simultaneously create, review, and publish data-linked documents and reports. Its proprietary, word processing, spreadsheet, and presentation applications are integrated and built a data management engine that allows work anytime from anywhere with an internet connection. The company serves Fortune 100 and Fortune 500 companies. For more information, visit the company's website at www.workiva.com.
Xenetic Biosciences (XBIO)
Xenetic Biosciences (NASDAQ: XBIO) is a clinical-stage biopharmaceutical company that focuses on the discovery, development and planned commercialization of human drug therapies for the treatment of various conditions. Its drug delivery platform systems include PolyXen for creating next generation biologic drugs; OncoHist for the development of oncology drugs focused on orphan indications; Virexxa for the treatment of progesterone receptor negative endometrial cancer; and ImuXen for the development of vaccines that can simultaneously deliver multiple active pharmaceutical ingredients. Its product candidates comprise ErepoXen, a polysialylated erythropoietin for the treatment of anemia in pre-dialysis patients with chronic kidney disease; and OncoHist, an orphan drug that is in pre-clinical stage of development for the treatment of refractory acute myeloid leukemia. The company is also developing a pipeline of drug candidates for next generation biologics and novel oncology therapeutics in various orphan disease indications. For more information, visit the company's website at www.xeneticbio.com.
XO Group (XOXO)
XO Group (NYSE: XOXO) provides consumer multiplatform media services to the wedding, pregnancy and parenting, and nesting markets. Its network of websites include brands such as The Knot, which offers wedding resources through wedding website and mobile apps, national and local wedding magazines, and nationally published books; The Bump, a pregnancy and parenting brand that provides personalized information, content, and tools for anyone at any stage of their journey from fertility to pregnancy and parenting through the toddler years; and The Nest, which focuses on young nesters setting up homes and navigating new lives together. The company also offers national online advertising products, including sponsored and brand-integrated content, digital and native banner advertisements, placement in our online search tools, and direct e-mail marketing. For more information, visit the company's website at www.xogroupinc.com.
Xplore Technologies (XPLR)
Xplore Technologies (NASDAQ: XPLR) develops, integrates and markets rugged mobile personal computer systems (PCs) in the United States, Canada and internationally. The company's products enable the extension of traditional computing systems to a range of field personnel, including energy pipeline inspectors, public safety personnel, warehouse workers, and pharmaceutical scientists. Xplore offers a line of iX104 tablet PCs that are designed to operate in various work environments, such as extreme temperatures, constant vibrations, rain, and blowing dirt and dusty conditions; and are fitted with a range of performance matched accessories comprising multiple docking station solutions, wireless connectivity alternatives, global positioning system modules, and biometric and smartcard modules, as well as traditional peripherals, such as keyboards, mice, and cases. For more information, visit the company's website at www.xploretech.com.
Yield10 Bioscience (YTEN)
Yield10 Bioscience (NASDAQ: YTEN) is an advanced biomaterials company that focuses on delivering sustainable solutions to the plastics industry. The company develops and commercializes technologies for the production of polymers and chemicals in microbes and plants. It produces a family of biopolymers found in nature called polyhydroxyalkanoates (PHA), which occur naturally in living organisms and are chemically similar to polyesters. Yield10's bio-based polymeric modifiers for rigid, semi-rigid, and flexible polyvinyl chloride compounds are used in construction materials and medical applications; PHA coatings for paper and cardboard; marine biodegradable micro powders for use in cosmetics and personal care products; and PHA biopolymers for functional biodegradation. For more information, visit the company's website at www.yield10bio.com.
Yuma Energy (YUMA)
Yuma Energy (NYSE: YUMA) is an independent exploration and production company focused on the acquisition, development and exploration for conventional and unconventional oil and gas resources, primarily in the U. S. Gulf Coast. The company has employed a 3-D seismic-based strategy to build a multi-year inventory of development and exploration prospects. Its current operations are focused on onshore assets located in Texas and Louisiana, where it is targeting the Woodbine, Eagleford, Austin Chalk, Tuscaloosa, Wilcox, Frio, Marg Tex and Hackberry formations. In addition, Yuma has a non-operated position in the Bakken Shale in North Dakota and operated positions in Kern and Santa Barbara Counties in California. For more information, visit the company's website at www.yumaenergyinc.com.
Zafgen (NASDAQ: ZFGN) is a biopharmaceutical company focused on developing therapeutics for patients suffering from obesity and obesity-related disorders. Its lead product candidate is the Beloranib, an injection, which is in phase III clinical trials for the treatment of obesity and hyperphagia in patients with Prader-Willi syndrome; that has completed phase II clinical trials to treat hypothalamic injury-associated obesity, including craniopharyngioma-associated obesity; and which has completed phase IIb clinical trials for the treatment of severe obesity in the general population. The company is also developing ZGN-839, a liver-targeted methionine aminopeptidase 2 (MetAP2) inhibitor that is in pre-clinical studies for the treatment of nonalcoholic steatohepatitis and abdominal obesity, as well as other second-generation MetAP2 inhibitors to treat severe obesity. For more information, visit the company's website at www.zafgen.com.
Zix (NASDAQ: ZIXI) provides email encryption, data loss prevention (DLP), and Bring-Your-Own-Device solutions to the healthcare, financial services, insurance, and government sectors in the United States. The company's Zix Email Encryption allows an enterprise to use policy-driven rules to determine which email messages should be sent securely to comply with regulations or company-defined policies. It also provides ZixDirectory, an email encryption community to share identities; ZixCorp's Best Method of Delivery, which is designed to deliver email based on the senders' and recipients' communications environment and preferences. For more information, visit the company's website at www.zixcorp.com.
Zosano Pharma (ZSAN)
Zosano Pharma (NASDAQ: ZSAN) is a clinical-stage specialty pharmaceutical company that develops a proprietary transdermal microneedle patch system to deliver drug formulations through the skin for the treatment of various indications. The company's product candidate is ZP-Triptan, a proprietary formulation of zolmitriptan used for the treatment of migraine, which has completed a Phase I clinical trial. Its product candidates also include ZP-PTH, a proprietary formulation of teriparatide that is used for the treatment of severe osteoporosis; and ZP-Glucagon, a proprietary formulation of glucagon that is intended for the emergency rescue of patients suffering from life-threatening, severe hypoglycemia. For more information, visit the company's website at www.zosanopharma.com.
Zynerba Pharmaceuticals (ZYNE)
Zynerba Pharmaceuticals (NASDAQ: ZYNE) is a specialty pharmaceutical company that focuses on developing and commercializing proprietary synthetic cannabinoid therapeutics formulated for transdermal delivery. The company's product candidates include ZYN002, which is in Phase I clinical trial for the treatment of refractory epilepsy, Fragile X syndrome, and osteoarthritis; and ZYN001 that is in preclinical stage for the treatment of fibromyalgia and peripheral neuropathic pain. For more information, visit the company's website at www.zynerba.com.